Efficacy and Safety Studies

Eli Lilly’s Oral GLP-1 Pill Matches Injectables in Weight and Blood Sugar Control

Phase 3 results show nearly 8% weight loss with tolerable side effects, setting the stage for a late-2025 obesity drug application